2019台灣生技月 Bio Taiwan 生物科技大展

2019 台灣生技月 南港展覽館

講師

Robert Gallagher

Session 2 – AI for Biotech & Healthcare
Date: 24 July (Wednesday)  14:00 – 18:00
Venue: 3F, Bldg. A, CTBC Financial Park, Ballroom B


 
​​

Dr. Robert Gallagher

Head, Biopharma Integrated Development Solutions 
IQVIA 

 
Based in Singapore, Dr Gallagher has over 17 years of experience in healthcare business operations, drug development, and healthcare investment advisory; in addition to several years of hospital medical practice.  Former roles include Region Head of Sanofi Oncology APAC, where he led the launches of 4 new products; Head Healthcare Equity Analyst at Macquarie Bank; and clinical development and launch roles at Merck, Sharpe & Dohme and Johnson & Johnson.

Dr Gallagher holds an MBA from the Australian Graduate School of Management; a Masters in Applied Finance and Investment from the Financial Services Institute of Australia; and a Bachelor of Medicine and Bachelor of Surgery from the University of Queensland.

IQVIA Biopharma Integrated Development Solutions provide strategic, commercial and technical advice/support to biotechnology and pharmaceutical enterprises with assets in late-stage preclinical or clinical development.  Utilising the unmatched end-to-end combination of expertise and data from IQVIA, Biopharma Integrated Development Solutions supports APAC-based clients with their commercial, investment, regulatory and clinical trial design decision-making and activities to support optimization of their pathway to global markets.

 


Session Speech Title & Synopsis:
Optimizing Development Decision Making: Integrating Clinical and Commercial Considerations

Drug development is a risky business. To make the right strategic decisions aimed at achieving the best end-result – multiple factors and perspectives including cost, time, risk and return need to be considered from an early stage.  A number of these considerations and relevant case studies will be discussed in this presentation.